Biosergen AB (BIOSGN.ST)
SEK 0.51
(-5.9%)
SEK 0.51
(-5.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.88 Million SEK | 93.58% |
| 2022 | -29.34 Million SEK | -35.44% |
| 2021 | -21.66 Million SEK | -3578.27% |
| 2020 | -589 Thousand SEK | -142.28% |
| 2019 | 1.39 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -12.16 Million SEK | -629.0% |
| 2024 Q1 | -1.66 Million SEK | 11.36% |
| 2023 Q4 | -1.88 Million SEK | 70.61% |
| 2023 FY | -1.88 Million SEK | 93.58% |
| 2023 Q3 | -6.4 Million SEK | 36.57% |
| 2023 Q2 | -10.1 Million SEK | 39.83% |
| 2023 Q1 | -16.78 Million SEK | 42.79% |
| 2022 Q2 | -5.72 Million SEK | 41.04% |
| 2022 Q1 | -9.7 Million SEK | 55.22% |
| 2022 FY | -29.34 Million SEK | -35.44% |
| 2022 Q4 | -29.34 Million SEK | -210.3% |
| 2022 Q3 | -9.45 Million SEK | -65.31% |
| 2021 Q2 | -40.9 Million SEK | 0.0% |
| 2021 Q4 | -21.66 Million SEK | 35.94% |
| 2021 Q3 | -33.82 Million SEK | 17.33% |
| 2021 FY | -21.66 Million SEK | -3578.27% |
| 2021 Q1 | - SEK | 0.0% |
| 2020 FY | -589 Thousand SEK | -142.28% |
| 2019 FY | 1.39 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 96.236% |
| Ziccum AB (publ) | -2.13 Million SEK | 11.886% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 90.121% |
| BioArctic AB (publ) | -606.58 Million SEK | 99.69% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 96.229% |
| Mendus AB (publ) | -96.29 Million SEK | 98.045% |
| Genovis AB (publ.) | -43.94 Million SEK | 95.715% |
| Intervacc AB (publ) | -88.16 Million SEK | 97.864% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 109.181% |
| Active Biotech AB (publ) | -33.2 Million SEK | 94.328% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 103.538% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 95.219% |
| Aptahem AB (publ) | 2.9 Million SEK | 164.738% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 99.436% |
| Kancera AB (publ) | -45.69 Million SEK | 95.879% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 99.428% |
| Fluicell AB (publ) | -2.76 Million SEK | 31.849% |
| Saniona AB (publ) | 40.44 Million SEK | 104.655% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 94.102% |
| Biovica International AB (publ) | -58.73 Million SEK | 96.794% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 95.836% |
| AcouSort AB (publ) | -23.98 Million SEK | 92.15% |
| Xintela AB (publ) | -7.8 Million SEK | 75.887% |
| Abliva AB (publ) | -57.24 Million SEK | 96.71% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 99.033% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 97.709% |
| OncoZenge AB (publ) | -12.62 Million SEK | 85.088% |
| Amniotics AB (publ) | -5.63 Million SEK | 66.566% |
| 2cureX AB (publ) | -13.4 Million SEK | 85.951% |
| CombiGene AB (publ) | -101.44 Million SEK | 98.144% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 12.864% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 134.87% |
| Camurus AB (publ) | -1.16 Billion SEK | 99.838% |
| Corline Biomedical AB | -17.01 Million SEK | 88.931% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 97.751% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 98.637% |
| I-Tech AB | -83.26 Million SEK | 97.738% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 101.398% |
| Cyxone AB (publ) | -16.67 Million SEK | 88.704% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 96.631% |
| Cantargia AB (publ) | -139.74 Million SEK | 98.653% |
| NextCell Pharma AB | -46.79 Million SEK | 95.976% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 98.546% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 93.592% |
| Nanologica AB (publ) | -9.38 Million SEK | 79.942% |
| SynAct Pharma AB | -61.75 Million SEK | 96.951% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 91.207% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 85.766% |
| LIDDS AB (publ) | -13.51 Million SEK | 86.064% |
| Lipum AB (publ) | -8.46 Million SEK | 77.755% |
| BioInvent International AB (publ) | -236.3 Million SEK | 99.203% |
| Alzinova AB (publ) | -21.22 Million SEK | 91.129% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 97.186% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 63.655% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 97.751% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -104.009% |
| Simris Alg AB (publ) | 85.07 Million SEK | 102.213% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 97.706% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 101.134% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 90.944% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 36.642% |